Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-016401
Filing Date
2023-10-12
Accepted
2023-10-12 16:15:29
Documents
35
Period of Report
2023-08-31

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20230831x10q.htm   iXBRL 10-Q 616046
2 EX-31.1 bzyr-20230831xex31d1.htm EX-31.1 11668
3 EX-31.2 bzyr-20230831xex31d2.htm EX-31.2 11952
4 EX-32.1 bzyr-20230831xex32d1.htm EX-32.1 6693
5 EX-32.2 bzyr-20230831xex32d2.htm EX-32.2 7123
  Complete submission text file 0001558370-23-016401.txt   2061170

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20230831.xsd EX-101.SCH 16718
7 EX-101.CAL bzyr-20230831_cal.xml EX-101.CAL 17513
8 EX-101.DEF bzyr-20230831_def.xml EX-101.DEF 44325
9 EX-101.LAB bzyr-20230831_lab.xml EX-101.LAB 140303
10 EX-101.PRE bzyr-20230831_pre.xml EX-101.PRE 90838
29 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20230831x10q_htm.xml XML 195413
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0229
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 231322887
SIC: 2835 In Vitro & In Vivo Diagnostic Substances